Skip to main content

Bisker-Leib Vered's Form 4 filing

Compass Therapeutics, Inc.CMPX · filed Nov 25, 2022

Accession no.
0001171843-22-007662
Filed
Nov 25, 2022
Trade date
Nov 22-25, 2022
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $103.7K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bisker-Leib VeredCIK 0001814093Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 22, 2022Common StockSSaleDisposed−14,929$4.19F2−$62,552.511,069,985Direct
Nov 23, 2022Common StockSSaleDisposed−9,569$4.30F2−$41,146.71,060,416Direct
Nov 25, 2022Common StockSSaleDisposed−2$4.36−$8.721,060,414Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.30 per share on November 22, 2022 and $4.15 to $4.43 on November 23, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)